EUVIMEDEUVIMED entdecken
Open Access

Photodynamic Diagnosis for Superficial Bladder Cancer: Do All Risk-Groups Profit Equally from Oncological and Economic Long-Term Results?

Wolfgang Otto, Maximilian Burger, Hans-Martin Fritsche, Andreas Blana, Wolfgang Roessler, Ruth Knuechel, Wolf F Wieland, Stefan Denzinger

Clinical medicine. Oncology · 2009

DOI: 10.4137/cmo.s1012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical medicine. Oncology, 2009. Verfasst von Wolfgang Otto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Regensburg, Germany. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Photodynamic diagnosis (PDD) of superficial bladder cancer decreases recurrence rates. We present oncological results of a randomized, prospective study, comparing transurethral resection (TUR) performed under conventional white light (WL) with PDD. The follow-up period is the longest reported to date. As costs might be reimbursed by prolonged recurrence-free survival in certain patients cost analysis in regard to risk-groups was performed. Material and methods Using chi-square test and log-rank test we compared recurrence rates of 103 patients after WL-TUR and of 88 patients after PDD-TUR. Cost analysis was performed according to risk-groups of recurrence.

Results

Mean follow-up was 99 months. Recurrence rate was 57% in WL vs. 28% in PDD (p < 0.001). Costs incurred by subsequent TUR averaged € 2310 per WL patient vs. € 713 per PDD patient. Savings per patient by PDD amounted to € 1597. PDD costs were reimbursed in low, intermediate and high risk patients, respectively.

Conclusions

PDD-TUR is significantly superior to conventional WL-TUR in terms of recurrence rate. While economic benefit is most prominent in intermediate risk patients, PDD related costs are reimbursed in all risk-groups.

Schlagwörter

Stichwörter der Autor:innen

cost analysisphotodynamicrecurrence ratesuperficial bladder cancertransurethral resectionurothelial carcinoma

Autor:innen und Institutionen

  • Department of Urology, University of Regensburg, Germany.

Zitieren

APA

Otto, W., Burger, M., Fritsche, H. M., Blana, A., Roessler, W., Knuechel, R., Wieland, W. F., & Denzinger, S. (2009). Photodynamic Diagnosis for Superficial Bladder Cancer: Do All Risk-Groups Profit Equally from Oncological and Economic Long-Term Results?. Clinical medicine. Oncology. https://doi.org/10.4137/cmo.s1012

Vancouver

Otto W, Burger M, Fritsche HM, Blana A, Roessler W, Knuechel R, et al. Photodynamic Diagnosis for Superficial Bladder Cancer: Do All Risk-Groups Profit Equally from Oncological and Economic Long-Term Results?. Clinical medicine. Oncology. 2009. doi:10.4137/cmo.s1012

BibTeX
@article{Otto2009,
  author = {Otto, Wolfgang and Burger, Maximilian and Fritsche, Hans-Martin and Blana, Andreas and Roessler, Wolfgang and Knuechel, Ruth and Wieland, Wolf F and Denzinger, Stefan},
  title = {Photodynamic Diagnosis for Superficial Bladder Cancer: Do All Risk-Groups Profit Equally from Oncological and Economic Long-Term Results?},
  journal = {Clinical medicine. Oncology},
  year = {2009},
  doi = {10.4137/cmo.s1012}
}
Kostenlos starten →